Development of information sharing in language neocortex in childhood-onset drug-resistant epilepsy.
Arya, R; Ervin, B; Wilson, JA; Byars, AW; Rozhkov, L; Buroker, J; Horn, PS; Scholle, C; Fujiwara, H; Greiner, HM; et al.
Epilepsia.
2019;
60:393-405.
Electroencephalographic Reporting for Refractory Status Epilepticus.
Sansevere, AJ; Arya, R; Sánchez Fernández, I; Gaillard, WD; Tasker, RC; Lai, YC; Anderson, AE; Tchapyjnikov, D; Chapman, KE; Brenton, JN; et al.
Journal of Clinical Neurophysiology.
2019;
36:365-370.
Bridging the childhood epilepsy treatment gap in northern Nigeria (BRIDGE): Rationale and design of pre-clinical trial studies.
Aliyu, MH; Abdullahi, AT; Iliyasu, Z; Salihu, AS; Adamu, H; Sabo, U; Garcia, JP; Abdullahi, SU; Mande, A; Xian, H; et al.
Contemporary Clinical Trials Communications.
2019;
15:100362-100362.
Investigation of bias in an epilepsy machine learning algorithm trained on physician notes.
Wissel, BD; Greiner, HM; Glauser, TA; Mangano, FT; Santel, D; Pestian, JP; Szczesniak, RD; Dexheimer, JW.
Epilepsia.
2019;
60:e93-e98.
The onset of pediatric refractory status epilepticus is not distributed uniformly during the day.
Sanchez Fernandez, I; Gainza-Lein, M; Abend, NS; Amengual-Gual, M; Anderson, A; Arya, R; Brenton, JN; Carpenter, JL; Chapman, KE; Clark, J; et al.
Seizure-European Journal of Epilepsy.
2019;
70:90-96.
A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy.
Helbig, I; Lopez-Hernandez, T; Shor, O; Galer, P; Ganesan, S; Pendziwiat, M; Rademacher, A; Ellis, CA; Hümpfer, N; Schwarz, N; et al.
The American Journal of Human Genetics.
2019;
104:1060-1072.
Changes in functional organization and functional connectivity during story listening in children with benign childhood epilepsy with centro-temporal spikes.
Vannest, J; Maloney, TC; Tenney, JR; Szaflarski, JP; Morita, D; Byars, AW; Altaye, M; Holland, SK; Glauser, TA.
Brain and Language.
2019;
193:10-17.
Using EHRs to advance epilepsy care.
Mbwana, JS; Grinspan, ZM; Bailey, R; Berl, M; Buchhalter, J; Bumbut, A; Danner, Z; Glauser, T; Glotstein, A; Goodkin, H; et al.
Neurology: Clinical Practice.
2019;
9:83-88.
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Lyden, P; Pryor, KE; Coffey, CS; Cudkowicz, M; Jr, SR N; Song, S; Rost, NS; Clarke Haley, E; Yankey, J; Magee, K; et al.
Annals of Neurology.
2019;
85:125-136.
Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine.
Ramsey, LB; Prows, CA; Zhang, K; Saldana, SN; Sorter, MT; Pestian, JP; Wenstrup, RJ; Vinks, AA; Glauser, TA.
Clinical Pharmacology and Therapeutics.
2019;
105:49-52.